Epizyme Overview
Valuation check: EPZM's ROE is 1053.76%, above the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow1053.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Epizyme (EPZM) currently reports a ROE of 1053.76%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore Epizyme's ROE history and peer comparisons.
Epizyme's ROE of 1053.76% is higher than the Healthcare sector average of 29.33%. That is roughly 3492.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Epizyme's current 1053.76% should be judged against Healthcare norms (sector average: 29.33%) and against EPZM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 1053.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Epizyme, and consider following EPZM for alerts when major investors trade the stock.
Epizyme is classified in the Healthcare sector. On ROE, it currently shows 1053.76% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EPZM with unrelated industries.
